The independent medical news service

Researchers report a marked decrease in the number of oncology clinical trials launched during the COVID-19 pandemic compared with the prepandemic period.

Black women with breast cancer are more likely than non-Hispanic White women to have a high-risk 21-gene Oncotype DX Breast Recurrence Score, and are more likely to die of breast cancer than their non-Hispanic White counterparts with a comparable score, US research shows.

A large proportion of systemic oncology therapies lack evidence of quality of life improvements at the time of regulatory approval by the US FDA and EMA, study findings indicate.

The clinical cell-cycle risk score is able to accurately predict metastasis risk in men undergoing dose-escalated radiation therapy, with or without androgen deprivation therapy, for intermediate- to high-risk localized prostate cancer, research suggests.

The phase 3 EV-301 trial has demonstrated significantly better overall survival with enfortumab vedotin than single-agent chemotherapy in advanced urothelial cancer patients who have previously received platinum-based chemotherapy and checkpoint inhibitors.

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

A post-hoc analysis of the JAVELIN Bladder 100 trial in the advanced urothelial carcinoma setting suggests that maintenance avelumab is beneficial regardless of the duration of prior chemotherapy, while another analysis shows the benefit in the Japanese patient subgroup.

Combination therapy with the HIF-2α inhibitor belzutifan and the multikinase inhibitor cabozantinib shows antitumor activity in people with metastatic clear cell renal cell carcinoma, phase 2 study data show.

The radiolabeled small molecule lutetium-177-prostate-specific membrane antigen-617 offers higher activity and better patient-reported outcomes than cabazitaxel in metastatic castration-resistant prostate cancer, research shows.

Combining a PD-1 inhibitor with docetaxel could benefit chemotherapy-naïve men with metastatic castration-resistant prostate cancer, suggest results from two early-phase trials.

The CLEAR study has demonstrated a significant progression-free survival gain with use of lenvatinib plus pembrolizumab for the first-line treatment of advanced clear cell renal cell carcinoma.

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

Cabozantinib offers significantly longer progression-free survival than sunitinib for patients with metastatic papillary renal cell carcinoma, the SWOG 1500 investigators say.

Further analysis of patients with nonmetastatic castration-resistant prostate cancer from the SPARTAN trial has identified molecular biomarkers associated with long-term responses to apalutamide.

Enfortumab vedotin may provide a platinum-free option for patients who have received prior immune checkpoint inhibitor therapy for advanced urothelial carcinoma and are unable to tolerate cisplatin, suggest phase 2 trial findings.

Results from the phase 3 CheckMate 274 trial support the adjuvant use of nivolumab in patients with muscle-invasive urothelial carcinoma at high risk for recurrence after surgery.

Early data from the SAKK 06/17 trial point to the feasibility of incorporating durvalumab into the perioperative treatment regimen of patients with resectable muscle-invasive urothelial carcinoma.

A large study has failed to find an association between receipt of androgen deprivation therapy and a reduced risk for SARS-CoV-2 infection.

Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer derive a significant radiographic progression-free survival benefit from the addition of apalutamide to abiraterone acetate, suggest phase 3 trial data.

The decrease in PSA screening in recent years may have come at the cost of increased levels of later-stage disease at prostate cancer diagnosis, suggests research presented at the 2021 Genitourinary Cancers Symposium.